Work

Candidemia in the ICU: Does Initial Antifungal Matter?*

Year: 2018

Type: editorial

Abstract: Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, Bethesda, MD Clinical Monitoring Research Program, Leidos Biomedical Research, NCI Campus at Frederick, Frederick, MD *See also p. 384. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. Supported, in part, with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E and by the Intramural Program of the National Institute of Allergy and Infectious Diseases, NIH. Drs. Bennett and Powers received support for article research from the National Institutes of Health. Dr. Bennett disclosed government work.

Source: Critical Care Medicine

DOI: 10.1097/ccm.0000000000002903

Authors: John E. Bennett, John H. Powers

Institutions: National Institutes of Health, National Institute of Allergy and Infectious Diseases, National Cancer Institute, Leidos Biomedical Research Inc. (United States)

Language: English

Topic: Antifungal resistance and susceptibility

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute